A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

Summary

The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety of guselkumab.

Timeline

Start

2022-09-27

Primary completion

2027-03-25

Completion

2027-03-25

Outcome

Met primary endpoint

release “Key ndings from the FUZION study TREMFYA met the primary endpoint of combined stula remission at Week 24” jnj.com ↗

Drugs

Indications